[go: up one dir, main page]

ES2084360T3 - Formulaciones de aerosoles exentas de clorofluorocarbonos. - Google Patents

Formulaciones de aerosoles exentas de clorofluorocarbonos.

Info

Publication number
ES2084360T3
ES2084360T3 ES92912490T ES92912490T ES2084360T3 ES 2084360 T3 ES2084360 T3 ES 2084360T3 ES 92912490 T ES92912490 T ES 92912490T ES 92912490 T ES92912490 T ES 92912490T ES 2084360 T3 ES2084360 T3 ES 2084360T3
Authority
ES
Spain
Prior art keywords
formulations
chlorofluorocarbon
free aerosols
optionally
aerosols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92912490T
Other languages
English (en)
Inventor
Julianne Berry
Joel A Sequeira
Imtiaz A Chaudry
Michael Kopcha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24863578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2084360(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2084360T3 publication Critical patent/ES2084360T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)

Abstract

SE PRESENTAN FORMULACIONES PARA AEROSOLES SUBSTANCIALMENTE LIBRES DE CLOROFLUOROCARBONOS PARA ADMINISTRACION ORAL Y/O NASAL. LAS FORMULACIONES COMPRENDEN 1,1,1,2,3,3,3 HEPTAFLUOROPROPANO, UN MEDICAMENTO, OPCIONALMENTE UN EXCIPIENTE Y OPCIONALMENTE UN SURFACTANTE. TAMBIEN SE DESCRIBEN METODOS DE TRATAMIENTO UTILIZANDO LAS FORMULACIONES.
ES92912490T 1991-06-10 1992-06-08 Formulaciones de aerosoles exentas de clorofluorocarbonos. Expired - Lifetime ES2084360T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71279191A 1991-06-10 1991-06-10

Publications (1)

Publication Number Publication Date
ES2084360T3 true ES2084360T3 (es) 1996-05-01

Family

ID=24863578

Family Applications (4)

Application Number Title Priority Date Filing Date
ES00122297T Expired - Lifetime ES2200771T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol no clorofluorocarbonadas.
ES92912490T Expired - Lifetime ES2084360T3 (es) 1991-06-10 1992-06-08 Formulaciones de aerosoles exentas de clorofluorocarbonos.
ES95102114T Expired - Lifetime ES2158911T5 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.
ES95102113T Expired - Lifetime ES2158910T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES00122297T Expired - Lifetime ES2200771T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol no clorofluorocarbonadas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES95102114T Expired - Lifetime ES2158911T5 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.
ES95102113T Expired - Lifetime ES2158910T3 (es) 1991-06-10 1992-06-08 Formulaciones en aerosol sin clorofluorocarbonos.

Country Status (26)

Country Link
US (1) US5474759A (es)
EP (5) EP0588897B1 (es)
JP (1) JP3323199B2 (es)
CN (1) CN1067578A (es)
AT (4) ATE134509T1 (es)
AU (1) AU2017592A (es)
CA (1) CA2111002C (es)
CZ (1) CZ271493A3 (es)
DE (4) DE69231992T2 (es)
DK (3) DK0656206T3 (es)
ES (4) ES2200771T3 (es)
FI (1) FI935464A0 (es)
GR (3) GR3019374T3 (es)
HK (1) HK185596A (es)
HU (1) HUT67449A (es)
IE (1) IE921847A1 (es)
IL (1) IL102131A0 (es)
MX (1) MX9202750A (es)
NO (2) NO934500D0 (es)
NZ (1) NZ243061A (es)
OA (1) OA09868A (es)
PT (2) PT656207E (es)
SK (1) SK140493A3 (es)
WO (1) WO1992022288A1 (es)
YU (1) YU59092A (es)
ZA (1) ZA924164B (es)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3905726A1 (de) * 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
ATE134509T1 (de) † 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
HUT67445A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2-tetrafluorethane
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
NZ246046A (en) * 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
EP0616524B1 (en) 1991-12-12 1998-10-07 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
ATE204743T1 (de) * 1991-12-18 2001-09-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ES2089357T3 (es) * 1991-12-31 1996-10-01 Hoechst Ag Formulacion medicinal en forma de aerosol.
AU699677B2 (en) * 1992-07-31 1998-12-10 Glaxo Group Limited Surfactant free aerosol formulations containing beclomathasone dipropionate
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
SG52459A1 (en) * 1992-12-09 1998-09-28 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
DE4322703A1 (de) * 1993-07-08 1995-01-12 Asta Medica Ag Druckgaspackungen unter Verwendung von Polyoxyethylen-glyceryl-fettsäureestern als Suspensionsstabilisatoren und Ventilschmiermittel
DE69424181T2 (de) * 1993-12-20 2000-10-19 Minnesota Mining And Mfg. Co., Saint Paul Flunisolide aerosolformulierungen
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
KR970701535A (ko) * 1994-03-14 1997-04-12 지울리아노 페트렐리 비타민 E를 함유하는 에어로졸 약물 제형(Aerosol drug formulations containing vitamin'E)
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
MX9800125A (es) * 1995-06-27 1998-03-31 Boehringer Ingelheim Kg Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
DE69731473T2 (de) * 1996-05-09 2005-10-27 Amrad Operations Pty. Ltd., Richmond Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
ID18137A (id) * 1996-08-29 1998-03-05 Schering Corp Formulasi-formulasi aerosol mometason furoat bebas klorofluorokarbon
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
EP1498115A1 (en) * 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US6192882B1 (en) * 1997-02-24 2001-02-27 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
EP0966958A4 (en) * 1997-03-14 2001-10-10 Fujisawa Pharmaceutical Co AEROSOL PREPARATION
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JP2001517692A (ja) * 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
EP2042161A1 (en) * 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US8466134B1 (en) 1998-06-26 2013-06-18 Athena Neurosciences, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6485747B1 (en) * 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
AU5397300A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
AU7859800A (en) * 1999-10-08 2001-04-23 Schering Corporation Topical nasal treatment
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
WO2002053190A2 (en) 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20110301569A1 (en) 2001-01-20 2011-12-08 Gordon Wayne Dyer Methods and apparatus for the CVCS
RU2204998C2 (ru) * 2001-02-16 2003-05-27 Физический институт им. П.Н.Лебедева РАН Способ повышения работоспособности организма
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
CA2495689A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
EP1542904B1 (en) * 2002-08-27 2008-01-16 Schering Corporation Process for producing metered dose inhaler formulations
RS51707B (sr) * 2002-12-12 2011-10-31 Nycomed Gmbh. Kombinacija leka sastavljena od r, r - formoterola i ciklezonida
WO2004110460A1 (en) * 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
DK1670482T4 (da) * 2003-09-16 2022-08-22 Covis Pharma B V Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
BRPI0415707A (pt) * 2003-10-20 2006-12-19 Schering Corp composições farmacêuticas
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
DK1711164T3 (da) 2004-01-21 2010-07-19 Schering Corp Fremgangsmåde til behandling af akut rhinosinusitis
WO2005077339A1 (en) * 2004-02-10 2005-08-25 E.I. Dupont De Nemours And Company Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
JP2007533706A (ja) * 2004-04-20 2007-11-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
AU2005247410A1 (en) * 2004-05-20 2005-12-08 Discovery Laboratories, Inc. Methods , systems and devices for noninvasive pulmonary delivery
US20060014698A1 (en) * 2004-07-14 2006-01-19 O'connor Michael F Nebulized pharmaceutical compositions for the treatment of bronchial disorders
EP1819329A2 (en) * 2004-08-04 2007-08-22 Schering Corporation Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
JP2006087815A (ja) * 2004-09-27 2006-04-06 Canon Inc 噴霧方法および該方法に基づく噴霧装置
US8028697B2 (en) 2005-04-28 2011-10-04 Trudell Medical International Ventilator circuit and method for the use thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
KR101348594B1 (ko) 2005-05-18 2014-01-07 노바르티스 아게 기관지 치료를 위한 밸브, 장치 및 방법
CA2622193A1 (en) 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
CA2641605A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
JP2009526062A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション 薬学的処方物
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2120875B1 (en) 2007-02-11 2018-07-11 Map Pharmaceuticals Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
EP2265309B1 (en) 2008-03-17 2015-12-16 Discovery Laboratories, Inc. Ventilation circuit adaptor and proximal aerosol delivery system
WO2010042553A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
CA2905402C (en) 2008-10-22 2017-02-28 Trudell Medical International Modular aerosol delivery system
JP6180012B2 (ja) 2009-09-04 2017-08-16 ラプター ファーマスーティカルズ，インコーポレイテッド 嚢胞性線維症を治療するためのエアロゾル化レボフロキサシンの使用
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
CN106942784A (zh) * 2017-04-14 2017-07-14 张玲 一种七氟代‑3‑甲氧基丙烷组合物
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2885427A (en) * 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3261748A (en) * 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
NL7708731A (nl) * 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) * 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4311863A (en) * 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
EP0057401B1 (en) † 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
DE3246081A1 (de) * 1982-12-13 1984-06-14 G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt Nitroglycerin-spray
WO1987005211A1 (fr) * 1986-03-10 1987-09-11 Kurt Burghart Preparation pharmaceutique et son procede de production
US4851595A (en) * 1987-07-07 1989-07-25 E. I. Du Pont De Nemours And Company Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane
US4910192A (en) † 1987-12-04 1990-03-20 Sri International Topically active steroidal anti-inflammatory agents
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
GB8828544D0 (en) * 1988-12-07 1989-01-11 Ici Plc Chemical process
GB8900267D0 (en) * 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
DE3905726A1 (de) * 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
US4945119A (en) * 1989-05-10 1990-07-31 The Dow Chemical Company Foaming system for rigid urethane and isocyanurate foams
AU633584B2 (en) * 1989-06-15 1993-02-04 Tokyo Tanabe Company Limited Aerosols of pyrido(1,2-a)pyrimidine compounds
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
DE4003270A1 (de) † 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
DE69131867T2 (de) * 1990-03-23 2000-05-18 Minnesota Mining And Mfg. Co., Saint Paul Anwendung von löslichen fluorhaltigen Tensiden zur Herstellung von Aerosol-Präparaten mit dosierter Abgabe
JPH05509085A (ja) * 1990-06-27 1993-12-16 ミネソタ　マイニング　アンド　マニュファクチャリング　カンパニー 投与量が計測されたエーロゾル配合物の製造のための可溶性フルオロ界面活性剤の使用
DE69124374T2 (de) * 1990-06-29 1997-06-19 Fisons Plc, Ipswich, Suffolk Druckaerosolzusammensetzung
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5254755A (en) * 1990-12-04 1993-10-19 Allied-Signal Inc. Partially fluorinated alkanols having a tertiary structure
US5290539A (en) * 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5182040A (en) * 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
ATE134509T1 (de) † 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US5314682A (en) * 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
US6068832A (en) † 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations

Also Published As

Publication number Publication date
CN1067578A (zh) 1993-01-06
JPH06511235A (ja) 1994-12-15
EP0588897B1 (en) 1996-02-28
DE69231992T2 (de) 2001-12-13
DK0656206T3 (da) 2001-10-08
EP0518600A1 (en) 1992-12-16
DE69208660D1 (de) 1996-04-04
SK140493A3 (en) 1994-10-05
US5474759A (en) 1995-12-12
DE69231992D1 (de) 2001-09-13
IL102131A0 (en) 1993-01-14
ATE203902T1 (de) 2001-08-15
ES2200771T3 (es) 2004-03-16
OA09868A (en) 1994-08-15
EP0656207A1 (en) 1995-06-07
EP1092430A1 (en) 2001-04-18
DE69208660T2 (de) 1996-07-11
EP0656206B1 (en) 2001-08-08
DK0588897T3 (da) 1996-03-18
ES2158911T5 (es) 2009-12-09
DK0656207T4 (da) 2009-11-30
ES2158911T3 (es) 2001-09-16
NO934500D0 (no) 1993-12-09
PT656206E (pt) 2001-11-30
AU2017592A (en) 1993-01-12
DE69233150T2 (de) 2004-06-24
ATE203901T1 (de) 2001-08-15
GR3037046T3 (en) 2002-01-31
DE69233150D1 (de) 2003-09-11
GR3037044T3 (en) 2002-01-31
FI935464A7 (fi) 1993-12-07
CZ271493A3 (en) 1994-07-13
EP0588897A1 (en) 1994-03-30
HUT67449A (en) 1995-04-28
PT656207E (pt) 2001-11-30
YU59092A (sh) 1994-12-28
ATE134509T1 (de) 1996-03-15
NZ243061A (en) 1993-09-27
HK185596A (en) 1996-10-11
MX9202750A (es) 1992-12-31
FI935464L (fi) 1993-12-07
DE69231994T3 (de) 2010-01-21
EP0656206A1 (en) 1995-06-07
DE69231994D1 (de) 2001-09-13
IE921847A1 (en) 1992-12-16
EP1092430B1 (en) 2003-08-06
EP0656207B2 (en) 2009-07-22
WO1992022288A1 (en) 1992-12-23
ES2158910T3 (es) 2001-09-16
JP3323199B2 (ja) 2002-09-09
NO934500L (no) 1993-12-09
DK0656207T3 (da) 2001-10-08
ATE246497T1 (de) 2003-08-15
ZA924164B (en) 1993-02-24
CA2111002C (en) 2000-08-22
DE69231994T2 (de) 2001-11-22
CA2111002A1 (en) 1992-12-23
FI935464A0 (fi) 1993-12-07
GR3019374T3 (en) 1996-06-30
EP0656207B1 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
ES2084360T3 (es) Formulaciones de aerosoles exentas de clorofluorocarbonos.
NO934499L (no) Ikke-klorfluorcarbonaerosolformuleringer
FI963424A0 (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
ATE196076T1 (de) Aerosol arzneiformulierungen
IS3957A (is) Aðferð til framleiðslu á þrýstingsúðasamsetningumtil inntöku lyfja með innöndun
BR1100339A (pt) Formulações de aerossol em solução de beclometasona
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
DK0804166T3 (da) Formulering med kontrolleret frigivelse (Albuterol)
ITRM910696A0 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
DK515489A (da) Dispergerbar laegemiddelformulering
MX9200728A (es) Formulacion farmaceutica adaptada para administracformulacion farmaceutica adaptada para administracion topica, para desordenes en la piel. ion topica, para desordenes en la piel.
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
DK0443848T3 (da) Nyt antiulcermiddel
NO910186L (no) Fremgangsmaate for fremstilling av et oralt inhalerbart, farmasoeytisk atropin-salbutamol-aerosolpreparat.
IL98199A (en) Pharmaceutical compositions containing a derivative of substituted l-valyl-l-prolinamide
SE9101687L (sv) Dikloranilinfoerening
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
KR100194995B1 (ko) 관상동맥성 심장질환,동맥경화증 및(또는)지방단백질 대사 이상 치료용 약제
EP0579765A4 (en) Method and composition for the treatment of herpes related disorders
FI932332A0 (fi) Nya pyridobenzoindolderivat, deras framstaellning och dessa innehaollande farmaceutiska preparat
ES2173550T3 (es) Uso de olanzapina para la fabricacion de un medicamento para la neuroproteccion.
DZ1600A1 (fr) Compositions pharmaceutiques anti-glaucomateurses et leur procédé d'obtention.
ES2026755A6 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
MX9203581A (es) Composiciones farmaceuticas de indolinas 3,3-disubstituidas, para administracion nasal.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 588897

Country of ref document: ES